Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Likely To Shatter Novel Approval Record In 2018

Executive Summary

With at least 40 pending novel products, FDA seems poised to break its 2017 approval record of 46, and could even reach 60.

You may also be interested in...



Complete Response Letters See Uptick With US FDA's Thumbs Down For Waylivra

In first half of 2018, CRLs were rarely issued for CDER-regulated novel agents, but FDA's rejection of Waylivra marks second in two weeks.

Keeping Track: Novel Approvals For Diacomit, Takhzyro And Oxervate; CRLs For Mallinckrodt And Allergan

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA’s Scorching August Agenda

Ten novel agents are among the pending applications with user fee goal dates in August 2018.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS123426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel